Ann: Proteomics bolsters executive team - CCO and CFO appointed, page-38

My responses in blue.

• Rapid rise in share price (the stock reached a SP level too high for it's risk profile based on the below IMO). SPECULATIVE This is my personal opinion, and why I exited the stock, not speculative.
• PromarkerD flopping in all jurisdictions it has launched in - no reason provided by Richard - just radio silence. VALID POINT BUT COVID IS WORLD FOCUS Are you saying COVID is the reason for the flops?
• No licencing deal with Jansen following the supposedly good result (I was lead to beleive that folloiwng this validation, PIQ would start selling in US). JANSEN HAS NOT FINISHED YET FOR DEAL Why not?
• New "validations" keep coming out randomly. How many times does it need to be validated? NONSENSE Look at the previous 2-3 years, all the validations that just kept being announced randomly. Not nonsense.
• Lack of business plan - it seems they are just aimlessly ticking some boxes here and there, but how these boxes link, or how many more boxes need to be ticked? Anyones guess since PIQ don't tell you - do they not know themselves? SOUNDS LIKE MORE NONSENSE Please point me to the business plan.
• No indication on timelines for cash flow from PromarkerD. TRUE BUT WE WAIT FOR JANSEN Refer to above question RE Jansen. And also what about cash flow from other jurisdictions? Surly it isnt dependant on Jansen? Or is it Jansen or nothing?